Patient and family engagement interventions on patients' safety in primary care: a systematic review and meta-analysis

Yan Pang*[1,2] & Anna Szücs*[3,7], Ignacio Ricci Cabello[4], Jaheeda Gangannagaripalli[5], Lay Hoon Goh[3], Foon Leng Leong[1], Li Fan Zhou[6], Jose M. Valderas[1,3,8]

[1]Department of Family Medicine, National University Health System, Singapore
[2]Alice Lee Center for Nursing Study, Yong Loo Lin School of Medicine, National University of Singapore
[3]Department of Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore
[4]Balearic Islands Health Research Institute (IdISBa) & CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
[5]NIHR ARC GM /Healthy Ageing research group, School of Health Sciences, The University of Manchester, Manchester, UK
[6]Department of Statistics & Data Science, National University of Singapore, Singapore
[7]Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Netherlands
[8]Centre for Research in Health Systems Performance, National University of Singapore, Singapore, Singapore

* These authors contributed to the work equally

Abstract

Background

Engaging patients and their families has been proposed and promoted as key strategy in patient safety. However, little is known about the translation of such an approach in primary care. This systematic review and meta-analysis sought to assess the effectiveness of interventions promoting patient and family engagement for patient safety in primary care based on randomised controlled trials (RCTs).

Methods

Five electronic databases (MEDLINE, CINAHL, Embase, Web of Science, and CENTRAL) were searched from inception to February 2023 with key words structured in four blocks (patient and family engagement; patient safety; primary care; randomised controlled trial). Two independent study team members screened each record. For studies reporting on similar safety outcomes, results were combined into meta-analyses. Risk of bias and level of certainty were accessed. Reporting followed PRISMA standards.

Results

Sixteen records were identified, among which eight completed RCTs. Interventions covered "Inform about Engagement" and "Empower" levels regarding patient/family engagement but did not reach the highest level of "Partner/Integrate." The interventions primarily targeted medication safety outcomes, with meta-analyses on adverse drug events and medication appropriateness (assessed categorically and continuously) showing no significant effects (Log OR=-0.32, 95%CI [-0.78, 0.14], OR=0.72, 95%CI [-0.32,0.16]; Log OR=-0.08, 95%CI [-0.32, 0.16], OR=0.92, 95%CI [0.73,1.17]; MD=0.56, 95%CI [-0.61, 1.72]). Overall risk of bias was low and the certainty of evidence ranged from moderate to high for most completed studies, except for adverse drug events, where certainty was rated low.

Conclusion

RCTs investigating interventions related to patient and family engagement in primary care patient safety are limited and yield inconclusive results. Patient engagement strategies should delve into more comprehensive levels of patient and family engagement and address diverse patient safety outcomes.

Key words: Patient involvement; patient engagement; family involvement; family engagement; patient safety; primary care; family medicine; randomized controlled trial.

- **What is already known on this topic**
  Involving patients and their families in patient safety has been advocated and emphasized as a crucial strategy. However, current reviews have yet to incorporate evidence evaluating the effectiveness of various intervention types and their impact on safety outcomes in the primary care setting.

- **What this study adds**
  This review provides a synthesis of available RCTs examining the effects of interventions on patient and family engagement and their impact on patient safety within the primary care context.

- **How this study might affect research, practice or policy**
  The findings from the review indicate that interventions targeting patient and family engagement did not exhibit a discernible impact on patient safety outcomes in the primary care setting. This underscores the imperative for more rigorous evaluations within this domain.

1 Introduction

Patient safety has gained momentum in the last decades, with patient safety strategies being integrated into the agendas of healthcare organizations worldwide (1). Nevertheless, the development of strategies and interventions to improve patient safety in healthcare delivery has by and large been confined to hospital care (2, 3). The delivery of care within the community settings relies substantially on patients and their families in the management of their health (4). Consequently, patient and family engagement hold particular relevance for patient safety outcomes in primary and community care, as it involves the help of precisely those stakeholders who are best positioned to identify errors or potential risks of harm at all stages (5, 6). Patient and family engagement goes beyond augmenting the awareness of patients and families regarding the factors influencing their care, encompassing the empowerment of these individuals to engage in discussion and, in more extensive cases – team up with healthcare professionals in order to prevent or mitigate adverse events (1).

Patient and family engagement strategies have already been considered a pillar of patient safety since the landmark report of the Institute of Medicine in 1999, *To Err is Human* (7), which recognized the potential of this approach to transform patient safety. Yet, only more recently has the need to focus on patient engagement been reaffirmed in the World Health Organisation's Declaration of Astana (8) and with WHO designating "Engaging patients for patient safety" as the theme for the 2023 World Patient Safety Day (9).

The prevalence of preventable patient harm in primary care appears to be lower and less severe than in hospital settings (10). However, 90% of health care contacts are contained within primary care (11) and the sheer number of patient-provider interactions together with the distinct nature of care in the community justify patient safety interventions to be tailored to primary care. The Organisation for Economic Co-operation and Development recently estimated that effective patient involvement could potentially diminish harm by up to 15% in ambulatory care and lead to significant cost savings for the healthcare system (12). Further, primary care appears a favourable environment to implement such strategies because of the sustained relationship between providers, patients, and families that is traditionally at its root (13). Despite

all this, there remains a notable scarcity of knowledge regarding patient and family engagement strategies to enhance safety in primary care settings (14, 15).

Specific interventions, such as face-to-face coaching sessions in older adults (16), family carer support in dementia (17), or the utilization of eHealth tools for reporting adverse drug effects (18) have demonstrated efficacy in engaging patients and families in primary care patient safety. The implementation of patient and family engagement strategies in patient safety has nonetheless been viewed by some authors as challenging (2) and has mainly been studied in the context of medication safety so far (18-20). Many patient safety strategies involving patient/family engagement have been systematically reviewed but remain insufficiently examined in intervention studies in primary care. These include patient-provider partnerships (21, 22), patient involvement in decision-making (23) or decision coaching (24), patient access to medical records (25), and patient-mediated interventions (26). All in all, it remains unclear which patient and family engagement interventions have reliably proven effective in primary care and for which patient safety outcomes (27).

The present systematic review and meta-analysis sought to synthesize the intervention characteristics and effects of patient and family engagement interventions tested in randomized controlled trials (RCTs) and aimed at improving patient safety outcomes in primary care.

2 Methods

We conducted a systematic review of published randomised clinical trials. The search protocol was preregistered on PROSPERO (registration number: CRD42023397495). Methods and reporting followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

2.1 Criteria for considering studies for this review

2.1.1 Definitions of key concepts

We used Coulter's definition of patient engagement (28): "*a set of reciprocal tasks between patients, healthcare professionals, and healthcare organizations working together to promote and support active patient and public involvement in health and*

healthcare and to strengthen their influence on healthcare decisions, at both the individual and the collective level" (29) and extended it to include patients' families.

Patient safety was defined as "*a health care discipline that aims to prevent and reduce risks, errors and harm that occur to patients during provision of health care*" (30).

<u>2.1.2 Eligibility criteria</u>

2.1.2.1 Types of studies

To be eligible, primary studies had to be randomised controlled trials (RCTs), including cluster-randomised trials. To maximize the sensitivity of our approach, we included trial registrations, published study protocols, pilot studies, and full-scale RCTs. We excluded non-randomised design, such as pre-post studies.

2.1.2.2 Types of participants

We included trials which recruited participants in primary care settings, such as private practices, family medicine clinics, community care settings, and other ambulatory care environments associated with general practice. Excluded were studies carried out in secondary or tertiary healthcare settings such as hospices or hospitals.

2.1.2.3 Types of interventions

We included interventions which (i) prompted patients and/or families to take actions in the context of their care; or (ii) focused on patient education which focused on engagement (e.g., informing patients or families about symptoms or red flags that should be reported to healthcare providers or about communication channels they can use); or (iii) for complex multifaceted interventions, only those interventions in which patient engagement was a significant component of the whole intervention, as evidenced by being reported separately (development and results) and being devoted substantial resources, such as time, manpower, and finance as compared to other components.

We excluded studies where interventions exclusively involved healthcare providers or policymakers, and studies where patient safety outcomes were not reported. We also excluded non-English language studies, review papers, and conference abstracts.

2.1.2.4 Types of outcome measures

We included studies that reported safety-related outcomes, such as adverse events leading to increased patients' morbidity/mortality or heightened risk of harm. Additionally, we considered studies where authors explicitly stated non-recommended medical practices. Variable related to quality of care but not to safety were excluded, as they were outside the scope of this study.

2.2 Information sources

Five electronic databases were searched for potentially eligible studies, including MEDLINE Ovid, CINAHL EBSCO, Embase Ovid, Web of Science Core Collection, and Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. We also performed reference tracking to check for additional eligible records.

2.3 Search strategy

The search strategy was based on key words used in published systematic reviews and refined with the National University of Singapore's libraries. It encompassed three blocks: patient and family engagement, patient safety, primary care, and randomised controlled trials (see the complete search strategy in the Supplement and the project's Open Science Framework repository: https://osf.io/sbacp/?view_only=6d6755e753b1411ab02dcb37f99a05aa).

2.4 Selection process

2.4.1 Record retrieval and deduplication

All retrieved records were downloaded into EndNote 20, where they were deduplicated following the method outlined by Bramer (31). The articles were transferred to the online software Rayyan for screening (32), where a second deduplication was performed.

<u>2.4.2 Screening process</u>

At each stage, each record was screened by two independent team members, working in pairs (YP, FLL, AS, IRC, JG, LHG). Discrepancies were resolved during consensus meetings involving the senior author (JMV).

Prior to each stage, the screening team performed a pilot screening, which involved the assessment by all team members of 50 randomly selected records for the title/abstract screening and 5 records for the full-text screening (for meeting conclusions, see: https://osf.io/sbacp/?view_only=6d6755e753b1411ab02dcb37f99a05aa).

2.5 Data collection process

Two study team members (YP and FLL) extracted all study information independently following the Template for Intervention Description and Replication checklist (33) in combination with the CONSORT 2010 Statement (34). The data extraction sheet was adapted from the Cochrane data collection guidelines (35) and is available at: https://osf.io/sbacp/?view_only=6d6755e753b1411ab02dcb37f99a05aa.
Discrepancies that arose during were resolved through consensus meetings involving a third team member (AS).

Raw outcome data was not reported for one study (36), which had to be excluded from the meta-analysis after two unsuccessful attempts to contact the authors by email.

2.6 Risk of bias assessment

Two team members, YP and FLL, conducted independent methodological quality assessments for each record using the Cochrane Risk of Bias tool version 2 (37). Discrepancies were resolved during a consensus meeting involving a third study team member (AS).

2.7 Synthesis methods

Records reporting on pilot and full-scale RCTs were grouped by outcomes (continuous versus discrete outcomes) and conceptual similarity (inappropriate prescriptions, side effects, others). For groups containing two or more studies, results were combined in meta-analyses using R's *metafor* package (38). In alignment with Cochrane guidelines (39), the longest follow-up times were selected to ensure a comprehensive analysis and accurate long-term effect estimates. When significant heterogeneity was present ($70\% > I^2 > 30\%$), the analysis defaulted to a multi-level random effects model to obtain a more accurate overall effect size. When heterogeneity was low ($I^2 < 30\%$), a fixed-effect model was employed using the Mantel-Haenszel method (40). Records unsuitable to be combined by meta-analysis were summarised through narrative synthesis.

In order to appraise the degree of patient and family engagement of each intervention, we adapted Kim and colleagues' (41) engagement framework by combining and extending some of the original categories (Table 1).

[TABLE 1 ABOUT HERE]

2.8 Certainty assessment

Following the GRADE approach (42), we rated the certainty of evidence as high, moderate, low, or very low, taking into consideration risk of bias, imprecision, inconsistency, indirectness, and publication bias. This was done by one researcher (IRC) and cross-checked by the rest of co-authors.

3 Results

3.1 Study selection

The systematic search yielded a total of 4,773 reports (Figure 1), of which 1,636 duplicates were removed prior to the screening process. Subsequently, 2,950 records were excluded after title and abstract screening, and an additional 14 during full text retrieval. Of the 173 reports retrieved for full text screening, a final set of 16 records were retained (Table 2).

[FIGURE 1 ABOUT HERE]

3.2 Study characteristics

3.2.1 General characteristics

All of the selected studies were published between 2001 and 2021 (Table 2). Five studies were cluster Randomized Controlled Trials (RCTs), three were standard RCTs, six were RCT protocols, and two were trial registration records.

Geographically, the selected records were distributed across regions, with seven from the United States, two from Germany, two from France, two from Spain (both reporting on the same project), one each from, respectively, Canada the United Kingdom, and Australia. The authors' country of affiliation matched where projects were carried out for all RCTs.

The follow-up duration across the selected studies ranged from two weeks to two years, and the number of randomized participants varied, with the sample sizes spanning from 100 to 1,601 participants.

[TABLE 2 ABOUT HERE]

3.2.2 Intervention characteristics

The included 16 records described 12 types of interventions (Table 2). In terms of levels of patient and family engagement, most interventions remained at the *Inform about engagement* level (n=8), a few were at the *Empower* level (n=4), and none reached the *Partner or Integrate* level (Figure 2). There were proportionally more patient engagement interventions reaching Level 2 among study protocols and registrations (2/6, 33.3%) than among completed RCTs (2/8, 25%), although publication dates did not indicate growing levels of patient and family engagement with time.

At the *Inform about engagement* level, the majority of interventions (n=5) involved the provision of information to patients or their families to increase their understanding of health management. For instance, polypharmacy patients partook in discussions with pharmacists about medication appropriateness and management (43), completed medication risk assessment forms during consultations with their general practitioners (44), were asked for feedback during consultations regarding safety outcomes (45), or regarding issues related to medication intake, with or without the aid of a computer assistant (46, 47), or were provided information through video or brochures that served as basis for discussion with their GPs (48-50). At the *Empower* level, interventions included educational initiatives on safety deprescribing (51), online platforms fostering communication between patients and GPs regarding drug safety (52), motivational/cognitive-behavioural therapy aimed at reducing reliance on opioids (53), and psychoeducational support promoting polypharmacy patients' understanding of their medication (54).

[FIGURE 2 ABOUT HERE]

Three studies included family members as participants: The intervention by Bayliss et al. (2020) involved education and activation strategies for patients and their families to promote deprescribing, Goggin and colleagues (2018 and 2022) utilized both video and brochures to promote communication between parents and general practitioners regarding antibiotic misuse in children.

3.2.3 Outcome characteristics

The patient safety outcomes examined were predominantly adverse drug events (n=8; 3 completed RCTs) and assessments of medication appropriateness (n=8; 6 were completed RCTs) (Table 2). One RCT protocol (48) listed both outcomes. Avoidable hospitalizations were reported by two records, of which no completed RCTs (45, 55).

3.3 Quality Assessment

Regarding risk of bias (Supplemental Figure 1), five RCTs demonstrated a relatively low overall risk of bias Studies conducted by Pit (44) and Fried (51) raised some concern, whereas one RCT (54) was assessed as having a high overall risk of bias.

3.4 Results of individual studies

Whereas most trial registrations and study protocols were either published within the previous two years or have already been followed by a publication on a corresponding RCT, none were found for one trial registration (53) and one published protocol (52) despite having been published eight to six years ago.

Patient and family engagement interventions have yielded inconclusive results regarding their impact on patient safety. Of the eight completed RCTs, four reported an improvement in the safety indicators associated with the patient engagement interventions studied. Improvements were reported in all completed RCTs (all from level 1 engagement) focusing on adverse drug events (44, 50, 54), but in only one (level 2 engagement; (43) out of four among those focusing on medication appropriateness. Three others, of which two full scale RCTs (level 1 engagement) (46, 49), one pilot RCT (level 1 engagement) (56) found no discernible impact on medication appropriateness. Further, a study investigating medication discrepancy correction (level 1 engagement) (51) reported no significant changes following the intervention, which was however not directly aligned with the outcome: the intervention consisted in patient and family education and activation about the value of

deprescribing whereas the patient safety outcome was the correction of medication discrepancies.

3.5 Impact on specific outcomes

We conducted three separate meta-analyses to analyse the outcomes related to adverse drug events and medication appropriateness, which combined evidence from six out of eight completed RCTs (Figure 3). For medication appropriateness, the analysis was separated in categorical outcomes for studies reporting presence vs absence of inappropriate prescriptions and continuous outcomes for studies using the Medication Appropriateness Index. One study by Muth 2016 reported both measures and was therefore included in both analyses.

The meta-analysis on adverse drug events (Figure 3, upper panel) did not include the cluster RCT by Buchet-Poyau (2021), given the difference in outcomes, namely promoting self-reporting of adverse drug events (with more reported adverse drug events considered more favourable) versus reducing adverse drug events in the other two studies (44, 54). In the combined analysis moderate heterogeneity was observed (I^2 = 62.8%). The multilevel random-effects model, following the DerSimonian and Laird method, yielded a LogOR of -0.32 (95% CI, -0.78 to 0.14, p = 0.178) and an OR of 0.72 (95% CI, 0.46 to 1.15). The certainty of the evidence for this meta-analysis was assessed as very low. A three-point downgrade was applied, attributable to the risk of bias arising from study design, indirectness resulting from reported proxy events, and imprecision associated with wide confidence intervals.

The meta-analysis of the three studies reporting medication appropriateness using the Medication Appropriateness Index score (43, 46, 56; Figure 3, middle panel) found moderate heterogeneity (I^2 = 39.5%) and a mean difference of Medication Appropriateness Index score of 0.56 (95%CI, -0.61-1.72, p = 0.35). The certainty of evidence for this meta-analysis was rated as moderate. The downgrading of evidence pertains to imprecision, attributed to the broad confidence intervals.

The meta-analysis of categorically measured medication appropriateness (count of inappropriate prescriptions; Figure 3, lower panel) included two studies (49, 56) with low heterogeneity (I^2 = 0%) found a LogOR of -0.08 (95%CI, -0.32 to 0.16, p = 0.514)

and an OR of 0.92 (95% CI, 0.73 to 1.17). We rated the certainty of the evidence as high for this meta-analysis.

Ultimately, the combined effect of interventions did not yield significant results in any of the meta-analyses.

[FIGURE 3 ABOUT HERE]

3.6 Certainty level

Based on our certainty assessment, evidence of the effectiveness of patient and family engagement versus standard of care had a low level of certainty for adverse drug events (n=2), a high level for medication appropriateness measured categorically (n=2), and a moderate level when measured continuously, with the Medication Appropriateness Index (n=3). Medication discrepancy correction also had a moderate level of certainty based on a single study (Supplemental Table 1).

4 Discussion

4.1 Statement of principal findings

Patient and family engagement is promoted based on its potential for transforming patient safety in healthcare. In our systematic review, we identified a limited number of interventions aimed at promoting patient and family engagement in the context of patient safety within primary care settings, totalling 16 in number. The scope of patient and family engagement remained limited, with none of these interventions offering patients and families the opportunity to influence level of overall care. All but one focused on medication safety as an outcome. While approximately half of all cluster RCTs and RCTs individually reported modest to moderate positive effects resulting from the interventions they examined, the meta-analyses conducted did not yield statistically significant findings for any of their combined effects.

Interventions eliciting patient and family engagement at the global care level were found in none of the included records. This aligns with findings from broader healthcare settings, where no study has achieved the integration of patients as full

care team members (41). The observed lack of effectiveness in certain interventions might be attributed to factors such as inadequate statistical power, which could be associated with insufficient follow-up durations or small sample sizes. This limitation might have been particularly pronounced in studies investigating relatively infrequent patient safety outcomes, such as falls. Additionally, the intervention had a considerable overlap with standard of care. Many of them offered additional consultation time or written information, which, while potentially assisted in identifying certain existing safety issues, might have been insufficient or too short-term to provide more important shifts in the mindsets or behaviours of patients or their families.

Apart from medication reconciliation, the evidence-based strategies of patient and family engagement recommended by the Agency for Healthcare Research and Quality (57) were not investigated. These strategies encompass elements such as being prepared to being engaged (patients and families encouraged to prepare for their appointments), teach-back (asking the patient/family to explain the instructions in their own words), and warm handoff (in-person handoff conducted in front of the patient).

Family involvement in the reported interventions was notably underexplored. In fact, only three records allowed for the inclusion of family members, with two such instances occurring within a paediatric setting (49, 58). Although the incorporation of family members can introduce complexities in terms of study design, trials can be adapted to accommodate the needs of both patients and families, e.g., by providing separate study information materials or using modified surveys for family members. Meanwhile, patient and family engagement remain a valuable resource in routine clinical practice, as research has demonstrated its potential to enhance communication between patients and healthcare providers during everyday primary care visits, evidenced by longer consultation times and patients taking a more active role during consultations (59).

Our review underscores the dearth of research into safety outcomes in primary care that extend beyond the scope of medication safety. This absence of investigation into outcomes such as errors occurring in other facets of healthcare processes, including communication errors or errors associated with care management, is noteworthy (7). These underexplored aspects are of particular significance, considering their potential frequency (60), with estimates indicating errors in approximately 4 out of every 1000 primary care encounters (61).

4.2 Strengths and limitations

The current review provides an in-depth and comprehensive overview of studies characterized by diverse objectives and scopes. It benefited from a comprehensive approach, including not only completed RCTs but also trial registrations and protocols, and a rigorous methodology, adhering to the Cochrane Collaboration guidelines at each step.

However, certain limitations emerge concerning the search strategy and the nature of the records. While the strategy was constructed based on published systematic reviews pertaining to patient safety and finalised after input from an information specialist (librarian), additional, unknown keywords might have generated more results related to domains other than medication safety. Similarly, the lack of a universally accepted definition for 'patient engagement' in the literature led to a broad spectrum of terms used to describe it in the context of patient safety. This variation in terminology may have resulted in the inadvertent omission of relevant records from our analysis. Our search strategy, which was limited to five electronic databases and focused solely on studies published in English in peer-reviewed journals, may have omitted pertinent records available in other languages or formats. Furthermore, a risk of bias was identified in three of the included records, thereby constraining the reliability of their findings.

4.3 Recommendations for policy, practice, and future research

We have not found compelling evidence for any of the specific approaches studied in the trials. The lack of such structured approaches should not deter primary care practitioners to consider how they can incorporate patient and family engagement in their practices. Future research should prioritize interventions promoting higher levels of patient and family engagement in the context of patient safety within primary care settings. There is also a compelling need to consider the inclusion of family members into the patient safety framework to obtain a more comprehensive and nuanced comprehension of patient safety.

5 Conclusions

Although patient and family engagement in patient safety in primary care is an appealing and promising area, there is a paucity of pertinent studies, and the existing evidence remains inconclusive. To address these gaps, future Randomized Controlled Trials take a broader approach by investigating a more comprehensive spectrum of primary care safety outcomes, transcending the limited scope of medication safety. These future investigations should encompass interventions that extend beyond health promotion, incorporating safety checks during additional consultations with healthcare professionals to elevate the level of patient and family engagement. Furthermore, the potential role of family members in augmenting the effectiveness of these interventions should be explored and harnessed by upcoming studies.

6 Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

7 Funding

This study was funded by the Technology and Compassion: improving patient outcomes through data analytics and patients´ voice in Primary Care.

8 Role of the funder/sponsor

The funding entity played no part in shaping or executing the study, gathering, overseeing, analyzing, or interpreting the data, preparing, reviewing, or endorsing the manuscript, nor in the decision to submit the manuscript for publication. The funds from the National Medical Research Council (NMRC) Clinical Research Coordinator Funding were allocated to sustain the remuneration of both YP and FLL.

References

1.   WHO. Global Patient Safety Action Plan 2021-2030 [online]. 2021. https://www.who.int/teams/integrated-health-services/patient-safety/policy/global-patient-safety-action-plan (accessed 01 December 2023).

2.   Kuriakose R, Aggarwal A, Sohi RK, Goel R, Rashmi N, Gambhir RS. Patient safety in primary and outpatient health care. Journal of family medicine and primary care. 2020;9(1):7.

3.   Marchon SG, Mendes Junior WV. Patient safety in primary health care: a systematic review. Cadernos de saúde pública. 2014;30:1815-35.

4.   Smith M, Saunders R, Stuckhardt L, McGinnis JM. Engaging patients, families, and communities. Best care at lower cost: The path to continuously learning health care in America: National Academies Press (US); 2013.

5.   Schenk EC, Bryant RA, Van Son CR, Odom-Maryon T. Perspectives on patient and family engagement with reduction in harm: the forgotten voice. Journal of nursing care quality. 2019;34(1):73-9.

6.   Domer G, Gallagher TM, Shahabzada S, Sotherland J, Paul EN, Kumar K-N, et al. Patient safety: preventing patient harm and building capacity for patient safety. Contemporary Topics in Patient Safety-Volume 1: IntechOpen; 2021.

7.   Donaldson MS. An overview of to err is human: re-emphasizing the message of patient safety. 2011.

8.   WHO. Global Conference on Primary Health Care [online]. 2018. https://www.who.int/publications/i/item/WHO-HIS-SDS-2018.61 (accessed 01 November 2023).

9.   WHO. World Patient Safety Day 2023: Engaging Patients for Patient Safety Advocacy Brief [online]. 2023. https://iris.who.int/bitstream/handle/10665/375011/9789240081987-eng.pdf (accessed 08 January 2024).

10.   Panagioti M, Khan K, Keers RN, Abuzour A, Phipps D, Kontopantelis E, et al. Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. bmj. 2019;366.

11.   WHO. Fact sheets-Primary health care [online]. 2023. https://www.who.int/news-room/fact-sheets/detail/primary-health-care (accessed 01 December 2023).

12.   Slawomirski L, Auraaen A, Klazinga N. The economics of patient safety in primary and ambulatory care: flying blind. OECD Health Working Papers. 2018;106.

13.   Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. The milbank quarterly. 2005;83(3):457-502.

14.   WHO. Global Expert Consultation on the WHO Framework on Patient and Family Engagement [online]. 2014. https://www.who.int/publications/m/item/global-expert-consultation-on-the-who-framework-on-patient-and-family-engagement (accessed on 01 December 2023).

15.　　Panesar SS, Desilva D, Carson-Stevens A, Cresswell KM, Salvilla SA, Slight SP, et al. How safe is primary care? A systematic review. BMJ quality & safety. 2016;25(7):544-53.

16.　　Wetzels R, Harmsen M, Van Weel C, Grol R, Wensing M. Interventions for improving older patients' involvement in primary care episodes. Cochrane Database of Systematic Reviews. 2007(1).

17.　　Powell C, Tomlinson J, Quinn C, Fylan B. Interventions for self-management of medicines for community-dwelling people with dementia and mild cognitive impairment and their family carers: a systematic review. Age and Ageing. 2022;51(5):afac089.

18.　　Lancaster K, Abuzour A, Khaira M, Mathers A, Chan A, Bui V, et al. The use and effects of electronic health tools for patient self-monitoring and reporting of outcomes following medication use: systematic review. Journal of medical Internet research. 2018;20(12):e294.

19.　　Coxeter P, Del Mar CB, McGregor L, Beller EM, Hoffmann TC. Interventions to facilitate shared decision making to address antibiotic use for acute respiratory infections in primary care. Cochrane Database of Systematic Reviews. 2015(11).

20.　　O'Sullivan JW, Harvey RT, Glasziou PP, McCullough A. Written information for patients (or parents of child patients) to reduce the use of antibiotics for acute upper respiratory tract infections in primary care. Cochrane Database of Systematic Reviews. 2016(11).

21.　　Lowe D, Ryan R, Schonfeld L, Merner B, Walsh L, Graham-Wisener L, et al. Effects of consumers and health providers working in partnership on health services planning, delivery and evaluation. Cochrane Database of Systematic Reviews. 2021(9).

22.　　Sharma AE, Knox M, Mleczko VL, Olayiwola JN. The impact of patient advisors on healthcare outcomes: a systematic review. BMC health services research. 2017;17:1-14.

23.　　Butterworth JE, Hays R, McDonagh ST, Richards SH, Bower P, Campbell J. Interventions for involving older patients with multi‐morbidity in decision‐making during primary care consultations. Cochrane Database of Systematic Reviews. 2019(10).

24.　　Jull J, Köpke S, Smith M, Carley M, Finderup J, Rahn AC, et al. Decision coaching for people making healthcare decisions. Cochrane Database of Systematic Reviews. 2021(11).

25.　　Davis Giardina T, Menon S, Parrish DE, Sittig DF, Singh H. Patient access to medical records and healthcare outcomes: a systematic review. Journal of the American Medical Informatics Association. 2014;21(4):737-41.

26.　　Fønhus MS, Dalsbø TK, Johansen M, Fretheim A, Skirbekk H, Flottorp SA. Patient‐mediated interventions to improve professional practice. Cochrane Database of Systematic Reviews. 2018(9).

27.　　Park M, Giap T-T-T. Patient and family engagement as a potential approach for improving patient safety: A systematic review. Journal of Advanced Nursing. 2020;76(1):62-80.

28.   WHO. Technical series on safer primary care: World Health Organization; 2017.

29.   Coulter A. Patient engagement—what works? The Journal of ambulatory care management. 2012;35(2):80-9.

30.   WHO. The conceptual framework for the international classification for patient safety Geneva [online]. 2009. https://www.who.int/publications/i/item/the-conceptual-framework-for-the-international-classification-for-patient-safety-(icps) (accessed 01 December 2023).

31.   Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. Journal of the Medical Library Association: JMLA. 2016;104(3):240.

32.   Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016;5:1-10.

33.   Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. Bmj. 2014;348.

34.   Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Journal of Pharmacology and pharmacotherapeutics. 2010;1(2):100-7.

35.   Cochrane. Chochrane training for Data collection form (for RCTs) [online]. 2021. https://training.cochrane.org/data-collection-form-rcts (acessed on 01 November 2023).

36.   O'Connor PJ, Sperl-Hillen J, Johnson PE, Rush WA, Crain AL. Customized feedback to patients and providers failed to improve safety or quality of diabetes care: a randomized trial. Diabetes Care. 2009;32(7):1158-63.

37.   Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj. 2019;366.

38.   Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of statistical software. 2010;36:1-48.

39.   Cochrane. Cochrane Handbook for Systematic Reviews of Interventions [online]. 2011. https://handbook-5-1.cochrane.org/chapter_9/9_3_4_repeated_observations_on_participants.htm (accessed 30 November 2023).

40.   Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. London, England: Cochran Collaboration. 2011.

41.   Kim JM, Suarez-Cuervo C, Berger Z, Lee J, Gayleard J, Rosenberg C, et al. Evaluation of patient and family engagement strategies to improve medication safety. The Patient-Patient-Centered Outcomes Research. 2018;11:193-206.

42.   Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of clinical epidemiology. 2011;64(4):380-2.

43. Syafhan NF, Al Azzam S, Williams SD, Wilson W, Brady J, Lawrence P, et al. General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial. Journal of Pharmaceutical Policy and Practice. 2021;14:1-15.

44. Pit SW, Byles JE, Henry DA, Holt L, Hansen V, Bowman DA. A Quality Use of Medicines program for general practitioners and older people: a cluster randomised controlled trial. Medical Journal of Australia. 2007;187(1):23-30.

45. Serrano-Ripoll MJ, Ripoll J, Llobera J, Valderas JM, Pastor-Moreno G, de Labry Lima AO, et al. Development and evaluation of an intervention based on the provision of patient feedback to improve patient safety in Spanish primary healthcare centres: study protocol. BMJ open. 2019;9(12):e031367.

46. Muth C, Uhlmann L, Haefeli WE, Rochon J, van den Akker M, Perera R, et al. Effectiveness of a complex intervention on Prioritising Multimedication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial. BMJ open. 2018;8(2):e017740.

47. Mangin D, Lamarche L, Agarwal G, Banh HL, Dore Brown N, Cassels A, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021;22(1):1-15.

48. Bayliss E, Shetterly S, Drace M, Norton J, Green A, Reeve E, et al. The OPTIMIZE patient-and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials. 2020;21:1-13.

49. Goggin K, Hurley EA, Lee BR, Bradley-Ewing A, Bickford C, Pina K, et al. Let's Talk About Antibiotics: a randomised trial of two interventions to reduce antibiotic misuse. BMJ open. 2022;12(11):e049258.

50. Buchet-Poyau K, Occelli P, Touzet S, Langlois-Jacques C, Figon S, Dubois J-P, et al. Improving patient self-reporting of antihypertensive adverse drug events in primary care: a stepped wedge cluster randomised trial. BMC Family Practice. 2021;22(1):165.

51. Fried TR, Niehoff KM, Street RL, Charpentier PA, Rajeevan N, Miller PL, et al. Effect of the tool to reduce inappropriate medications on medication communication and deprescribing. Journal of the American Geriatrics Society. 2017;65(10):2265-71.

52. Bailey SC, Paasche-Orlow MK, Adams WG, Brokenshire SA, Hickson RP, Oramasionwu CU, et al. The electronic medication complete communication (EMC2) study: Rationale and methods for a randomized controlled trial of a strategy to promote medication safety in ambulatory care. Contemporary clinical trials. 2016;51:72-7.

53. NCT. Primary Care Intervention to Reduce Prescription Opioid Overdoses (POST) [online]. 2015. https://classic.clinicaltrials.gov/ct2/show/NCT02464410?term=NCT02464410&draw=2&rank=1 (accessed 10 June 2023).

54. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Annals of Pharmacotherapy. 2001;35(7-8):835-40.

55.   NCT. Improving Patient Safety in Spanish Primary Care (PC) Centres (SinergiAPS): Clinical trial gov [online]. 2019. https://classic.clinicaltrials.gov/ct2/show/NCT03837912?term=NCT03837912&draw=2&rank=1 (accessed 10 June 2023).

56.   Muth C, Harder S, Uhlmann L, Rochon J, Fullerton B, Güthlin C, et al. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ open. 2016;6(7):e011613.

57.   Smith K, Baker K, Wesley D, Zipperer L, Clark MD, Hanneke CR, et al. Guide to Improving Patient Safety in Primary Care Settings by Engaging Patients and Families. Agency for Healthcare Research and Quality Published online. 2017.

58.   Goggin K, Bradley-Ewing A, Myers AL, Lee BR, Hurley EA, Delay KB, et al. Protocol for a randomised trial of higher versus lower intensity patient–provider communication interventions to reduce antibiotic misuse in two paediatric ambulatory clinics in the USA. BMJ open. 2018;8(5):e020981.

59.   Wolff JL, Clayman ML, Rabins P, Cook MA, Roter DL. An exploration of patient and family engagement in routine primary care visits. Health Expectations. 2015;18(2):188-98.

60.   Harrison R, Walton M, Manias E, Smith–Merry J, Kelly P, Iedema R, et al. The missing evidence: a systematic review of patients' experiences of adverse events in health care. International Journal for Quality in Health Care. 2015;27(6):424-42.

61.   Michel P, Brami J, Chanelière M, Kret M, Mosnier A, Dupie I, et al. Patient safety incidents are common in primary care: A national prospective active incident reporting survey. PLoS One. 2017;12(2):e0165455.

Table 1: Levels of patient and family engagement

Levels		Definitions	Level of impact
Level 1	Inform about engagement	Patients receiving information (e.g., booklets) to learn about their health and increase communication with their care team	Patient's individual level of care
Level 2	Empower	Patients acquiring new skills and/or tools to engage with care team	
Level 3	Partner/Integrate	Patients involved in decision-making as collaborators, consultants, or team members	Overall clinical care

Note. Framework adapted from Kim et al. 2017 and encompassing three levels of engagement ordered with respect to increasing patient and family involvement. While patients or families' involvement impacts individual care at Levels 1 and 2, their involvement at level 3 aims to influence patients' overall care.

Table 2: Study characteristics

Author, year	Type of record	Country/setting	Interventions[a] and their level of patient/family engagement	Study groups (n per group; control intervention)	Patient safety outcome[b]	Follow-up timepoints/follow-up duration	Results pertaining to patient/family engagement in patient safety	Outcome statistics
Outcome: adverse drug events (ADE)								
Bailey, S. C., et al. (2016)	Cluster RCT protocol	USA/ambulatory care	Electronic medication communication tool to facilitate communication between patients and physicians about drug safety *Level 2: Empower*	I: 480 C: 480 Standard care	ADE	Baseline, 4 weeks & 3 months / 3 months	NA	N=960
Bayliss, E. A., et al. (2020)[c]	Cluster RCT protocol	USA/primary care clinics	Short, automated information sheet to prompt discussion with GP about medication discrepancies *Level 1: Inform about engagement*	I: 1814 C: 1857 Waitlist control	Specific ADE (falls, haemorrhagic events, and hypoglycaemic events); Potential inappropriate medicine	6 months, 12 months / 2 years	NA	N=3671
Mangin, D., et al. (2021)	RCT protocol	Canada/primary care clinics	Patients asked about medication intake and related problems *Level 1: Inform about engagement*	I: 180 C:180 Waitlist control	Fall and other serious adverse events	Baseline, 6 months / 6 months	NA	N=360
Keriel-Gascou, M., et al. (2013)[d]	Cluster RCT protocol	France/general practitioner clinics	Interactive patient booklet as support for discussion with GP *Level 1: Inform about engagement*	I: 546 C: 549 Standard care	Increase in patient reporting of ADE	3 months / 3 months	Increase in reporting of adverse drug events	No. of patients reported ADEs: I:57/546; C:34/549. OR=3.9 95% CI [1.4-11.2], p=0.01, aOR=3.5, 95%CI [1.2-10.1], p=0.02
Buchet-Poyau, K., et al. (2021)[d]	Cluster RCT							
Jameson, J. P. and G. R. VanNoord (2001)	RCT	USA/physician practice clinics	Assessment of polypharmacy patients' understanding of medications & psychoeducation *Level 2: Empower*	I: 179 C:161 Standard care	ADE: combination of 18 symptoms commonly attributed to ADEs	Baseline, 6 months / 6 months	Improvement of symptoms attributed to ADEs	No. of patients reported symptoms improvement: I:67/179, C:58/161, p=0.24
Pit, S. W., et al. (2007)	Cluster RCT	Australia/general practices	Patients completing medication risk	I: 452 C: 397	Specific ADEs: slipped, tripped or stumbled OR falls	Baseline, 4 months, 12 months / 12 months	Decrease in reported fall events in the intervention group.	No. of patients reported fall events at 12 months: I:70/397,

			assessment with their doctor *Level 1: Inform about engagement*	Completed a Medication Risk Assessment forms but did not pass to GPs	OR fainted, felt weak or dizzy[e]		C:94/352. COR (95%CI):0.57 (0.40–0.81) p=0.0036; AOR (95% CI):0.61 (0.41–0.91) p=0.02
Outcome: medication appropriateness
Goggin, K., et al. (2018)[f,g]	Cluster RCT protocol	USA/private practice outpatient clinics	Video & brochure for parents on antibiotic misuse in children & encouraged to discuss issues with GP *Level 1: Inform about engagement*	I: 697 C: 904 Lower intensity intervention group and usual care	Patients receiving an inappropriate antibiotic prescription	2 weeks / 2 weeks	Intervention has no impact on inappropriate prescription	No. of patients received inappropriate prescription: I: 54/697, C: 85/904, adjusted OR 0.99; 95% CI 0.52 to 1.89, p=0.98
Goggin, K., et al. (2022)[f,g]	Cluster RCT							
Muth, C., et al. (2016)[h]	Cluster RCT	Germany/general practices	Computer-assisted discussion with patient on medication intake & polypharmacy evaluation/reduction *Level 1: Inform about engagement*	I: 50 C:50 Standard care	Medication appropriateness *Assessed continuously, with the Medication Appropriateness Index as well as categorically*	Baseline, 6 weeks, 3 months / 3 months	Intervention has no impact on inappropriate prescription nor medication appropriateness	No. of Inappropriate prescriptions per group (%) at 3 months: I: 107/392(27.2); C: 99/371(26.7) Changes of MAI score at 3 months: I: M(SD) 0.7(5.45) n=46; C: M(SD) -0.2(5.17) n=47; ICC/ICCadj: 0.030/0.039 p=0.460
Muth, C., et al. (2018)[h]	Cluster RCT			I: 252 C:253 Standard care		Baseline, 6 months, 9 months / 9 months	Intervention has no impact on medication appropriateness	MAI score at 9 months: I: M(SD) 4.8 (5.2) n=238; C: T2: M(SD) 3.9 (4.9) n=228; ICC/ICCadj: 0.000/0.00
Syafhan, N. F., et al. (2021)	RCT	UK/general practices	Polypharmacy patients involved in discuss with pharmacist about medication appropriateness and management *Level 1: Inform about engagement*	I: 181 C: 175 Standard care	Medication appropriateness *Assessed continuously, with the Medication Appropriateness Index*	Baseline, 6 months/ 6 months	Improvement of Medication Appropriateness Index scores.	Changes of Medication Appropriateness Index score at 6 months: I: M(SD) 2.4 (4.8) n=63; C: M(SD) 0.0(4.0) n=60; p=0.879
Outcome: other outcomes

				I: 225 C: 225				
Nct(2015)	RCT trial registration	USA/primary care clinic	Motivational & cognitive behavioural therapy on reducing reliance on opioids *Level 2: Empower*	Enhance usual care (provides educational content related to the biology of pain response and an overview of pain conditions usual care)	Patients with non-fatal overdose experiences or level of oversedation as an opioid side effect	Baseline, 3,6,12 months / 12 months	NA	N=450
Nct (2019)[i]	Cluster RCT trial registration	Spain/primary care centres	Patients asked to give feedback about experiences and outcomes related to patient safety *Level 1: Inform about engagement*	I: 624 C: 624 Control group will receive the feedback reports at the end of the study	Avoidable hospitalisation	Baseline, 12 months / 12 months	NA	N=1248
Serrano-Ripoll, M. J., et al. (2019)[i]	Cluster RCT protocol							
Fried, T. R., et al. (2017)	RCT	USA/primary care clinics	Education & activation of patients & families about value of deprescribing *Level 2: Empower*	I: 64 C: 64 Standard care	Patients with medication discrepancy correction	Baseline, 3 months / 3 months	The intervention has no effect on medication discrepancy correction	No. of patients with medication discrepancies correction: I: 46/64; C: 7/32; p=0.42

RCT: randomized controlled trial; ADE: adverse drug event; GP: General Practitioner; MAI: medication appropriateness index; I: intervention; C: control

[a] Only patients and/or family engagement were extracted from broader interventions, as most also involved general practitioners, pharmacists or other healthcare professionals.

[b] Only patient safety results were extracted from all reported outcomes.

[d,f,h,i] Studies used the same intervention.

[e] Falls were chosen as the outcome to include in the meta-analysis, as they were deemed the most severe ADE from all those reported.

[g&c] Studies interventions involved parent-child dyads and both patients and family members respectively.

Figure 1 PRISMA Chart summarising the screening process

Note. Under "Reasons for exclusion", some records met more than one exclusion criteria and were therefore counted in several categories.

Figure 2: Interventions classified by level of patient and family engagement

Figure 3: Meta-analyses of RCTs and cluster RCTs included in the review.

Outcome: adverse drug events assessed categorically

Outcome: Medication Appropriateness Index (MAI)

Outcome: medication appropriateness assessed categorically

Supplemental Figure 1: Risk of bias assessment of included cluster RCTs and RCTs

Note. Concerns regarding risk of bias primarily arose due to either significant deviations from the intended interventions or the presence of missing outcome data.

Supplemental Table 1： Patient and family engagement compared to standard of care for improve patient safety

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	patient involvement	usual care	Relative (95% CI)	Absolute (95% CI)	

Adverse drug events (follow-up: median 6 months)

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	patient involvement	usual care	Relative (95% CI)	Absolute (95% CI)	Certainty
2[1,2]	randomised trials	serious[a]	not serious	serious[b]	serious[c]	none	194/1122 (17.3%)	186/1062 (17.5%)	**OR 0.7261** (0.4584 to 1.1503)	**42 fewer per 1000** (from 86 fewer to 21 more)	⊕◯◯◯ Very low

Medication appropriateness

Inappropriate prescription (number of patients receiving an inappropriate prescription) (follow-up: mean 8 weeks)

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	patient involvement	usual care	Relative (95% CI)	Absolute (95% CI)	Certainty
2[3,4]	randomised trials	not serious	not serious	not serious	not serious	none	161/1090 (14.8%)	184/1275 (14.4%)	**OR 0.9231** (0.7261 to 1.1735)	**10 fewer per 1000** (from 35 fewer to 21 more)	⊕⊕⊕⊕ High

Medication appropriateness index (MAI score) (follow-up: median 6 months)

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	patient involvement	usual care	Relative (95% CI)	Absolute (95% CI)	Certainty
3[3,5,6]	randomised trials	not serious	not serious	not serious	serious[c]	none	347	335	-	**MD 0.56** (0.61 lower to 1.72 higher)	⊕⊕⊕◯ Moderate

Medication discrepancy correction (follow-up: mean 3 months)

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Effect	Certainty
1[7]	randomised trials	serious[d]	not serious	not serious	not serious	none	No differences between intervention and control patients in the number of medications prescribed at ninety days or in the number of TRIM-related recommendations implemented However, over three times as many patients who received the intervention had correction of medication reconciliation errors as those who did not (48.4% versus 14.3%, p < .001)	⊕⊕⊕◯ Moderate

CI: confidence interval; **MD:** mean difference; **OR:** odds ratio

Explanations

a. Pit 2007 presents some concerns due to deviations from the intended interventions and missing outcome data. Jameson 2001 presents a high risk of bias due to deviations from the intended intervention.

b. Falls reported as a proxy of adverse drug events in Pit 2007

c. Wide confidence intervals

d. Some concerns due to deviations from the intended intervention

References

1.Pit, S. W., Byles, J. E., Henry, D. A., Holt, L., Hansen, V., Bowman, D. A.. A Quality Use of Medicines program for general practitioners and older people: a cluster randomised controlled trial. Med J Aust; Jul 2 2007.

2.Jameson, J. P., VanNoord, G. R.. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother; Jul-Aug 2001.

3.Muth, C., Harder, S., Uhlmann, L., Rochon, J., Fullerton, B., Güthlin, C., Erler, A., Beyer, M., van den Akker, M., Perera, R., Knottnerus, A., Valderas, J. M., Gerlach, F. M., Haefeli, W. E.. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ Open; Jul 25 2016.

4.Goggin, K., Hurley, E. A., Lee, B. R., Bradley-Ewing, A., Bickford, C., Pina, K., Donis de Miranda, E., Yu, D., Weltmer, K., Linnemayr, S., Butler, C. C., Newland, J. G., Myers, A. L.. Let's Talk About Antibiotics: a randomised trial of two interventions to reduce antibiotic misuse. BMJ Open; Nov 21 2022.

5.Syafhan, N. F., Al Azzam, S., Williams, S. D., Wilson, W., Brady, J., Lawrence, P., McCrudden, M., Ahmed, M., Scott, M. G., Fleming, G., Hogg, A., Scullin, C., Horne, R., Ahir, H., McElnay, J. C.. General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial. J Pharm Policy Pract; Jan 4 2021.

6.Muth, C., Uhlmann, L., Haefeli, W. E., Rochon, J., van den Akker, M., Perera, R., Güthlin, C., Beyer, M., Oswald, F., Valderas, J. M., Knottnerus, J. A., Gerlach, F. M., Harder, S.. Effectiveness of a complex intervention on Prioritising Multimedication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial. BMJ Open; Feb 24 2018.

7.Fried, T. R., Niehoff, K. M., Street, R. L., Charpentier, P. A., Rajeevan, N., Miller, P. L., Goldstein, M. K., O'Leary, J. R., Fenton, B. T.. Effect of the Tool to Reduce Inappropriate Medications on Medication Communication and Deprescribing. J Am Geriatr Soc; Oct 2017.